Systemic treatment for acne working group report;Traitement de l'acne par voie generale: Argumentaire

Annales de Dermatologie et de Venereologie

Volumn 126, Issue 3, 1999, Pages 224-231

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; DOXYCYCLINE; ERYTHROMYCIN; ESTROGEN; GESTAGEN; GLUCONATE ZINC; ISOTRETINOIN; JOSAMYCIN; LYMECYCLINE; MINOCYCLINE; ORAL CONTRACEPTIVE AGENT; ROXITHROMYCIN; TETRACYCLINE; ANTIANDROGEN; ANTIINFECTIVE AGENT; CYPROTERONE ACETATE; DERMATOLOGICAL AGENT; ESTRADIOL DERIVATIVE; ETHINYLESTRADIOL; GLUCONIC ACID; KERATOLYTIC AGENT; LITHIUM; ZINC;

ACNE; ACNE FULMINANS; ARTICLE; CLINICAL FEATURE; DRUG INDICATION; GRAM NEGATIVE BACTERIUM; HUMAN; HYPERANDROGENISM; ORAL DRUG ADMINISTRATION; PROPIONIBACTERIUM ACNES; ACNE VULGARIS; CLASSIFICATION; FOLLOW UP; PATHOLOGY;

ACNE VULGARIS; ADMINISTRATION, ORAL; ANDROGEN ANTAGONISTS; ANTI-BACTERIAL AGENTS; CYPROTERONE ACETATE; DERMATOLOGIC AGENTS; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FOLLOW-UP STUDIES; GLUCONATES; HUMANS; ISOTRETINOIN; KERATOLYTIC AGENTS; LITHIUM; ZINC;

EID: 0033040870     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Recommandations et Références Médicales (ANDEM). Acné: traitement de l'acné par voie générale: indications, problèmes posés. Concours Med 1997;30:2233-7.
2. Cunliffe WJ, Cotterill JA. The acne: Clinical features, pathogenesis and treatment. London: WB Saunders, 1975.
3. Kligman AM. An overview of acne. J Invest Dermatol 1974;62:268-87.
4. e ed. 726 pages. Berlin: Springer Verlag, 1993.
5. Koo J. The psycholosocial impact of acne: patient's perceptions. J Am Acad Dermatol 1995;32:526-530.
6. Lucky AW, Biro FM, Loretta A, Simbarti LA, Morrison JA, Sorg NW. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Pediatr 1997;130:30-9.
7. American Academy of Dermatology: Systemic antibiotics for treatment of acne vulgaris: Efficacy and safety. Arch dermatol 1975;111:1630-6.
8. Allen BS, Smith G. Various parameters for grading acne vulgaris. Arch Dermatol 1982;118:23-5.
9. Burke BM, Cunliffe WJ. The assessment of acne vulgaris - the Leeds technique. Br J Dermatol 1984;111:83-92.
10. Cook CH, Centner RL, Michaels SE. An acne grading method using photographic standards. Arch Dermatol 1979;115:571-5.
11. Plewig G, Kligman AM. Classification of acne vulgaris. In: Acne: morphogenesis and treatment. Berlin: Springer Verlag, 1975.
12. Pochi PE, Shalta AR, Strauss JS, Webster SB. Report of the consensus conference on acne classification. J Am Acad Dermatol 1991;24:495-500.
13. Gammon WR, Meyer C, Lantis S, et al. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. A double-blind study. J Am Acad Dermatol 1986;14:183-6.
14. Gratton D, Raymond GP, Guertin-Larochelle S, Maddin SW, Leneck CM, Warner J, Collins JP, Gaudreau P, Bendl BJ. Topical clindamycin versus systemic tetracycline in the treatment of acne. J Am Acad Dermatol 1982;7:50-3.
15. Greenwood R, Burke B, Cunliffe WJ. Evaluation of a therapeutic strategy for the treatment of acne vulgaris with conventional therapy. Br J Dermatol 1986;114:353-8.
16. Hubbell CG, Hobbs ER, Rist MT, White CJ. Efficacy of miriocycline compared with tetracycline in treatment of acne vulgaris. Arch Dermatol 1982;118:989-92.
17. Khanna N. Treatment of acne vulgaris with oral tetracyclines. Indian J Dermatol Venereol Leprol 1993;59:74-6.
18. Plewig G, Petrozzi JW, Berendes U. Double-blind study of doxycycline in acne vulgaris. Arch Dermatol 1970;101:435-8.
19. Waskiexicz W, Grosshans E. Traitement de l'acné juvenile par les cyclines de deuxième génération: étude comparative randomisée doxycycline 50 mg/jour versus minocycline 100 mg/jour. Nouv Dermatol 1992;11:8-11.
20. Bundino S, Salomone R, Zina AM.Valutazione clinica della josamicina nella terapia dell'acne. G Ital Dermatol Venereol 1989; Nov-Dec-124:11-12.
21. Cunliffe WJ, Grosshans E, Belaich S, Meynadier J, Alirezai M, Thomas L. A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Eur J Dermatol 1998;8: 161-6.
22. Akamatsu H, Nishijima S, Adamatsu M, Kurokawa I, Asada Y. Clinical evaluation of roxithromycin in patients with acne. J Intern Med Res 1996;24:109-14.
23. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996;134:693-5.
24. Bjellerup M, Ljunffren B. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema. Br J Dermatol 1994;130:356-60.
25. Bjellerup M, Ljunffren B. Double-blind cross-over studies on phototoxicity of three tetracycline derivatives in human volunteers. Photodermatol 1987;4:281-7.
26. Beneton N, Bocquet H, Cosnes A, Revuz J, Roujeau JC. Benefit-risk assessment of acne therapies. Lancet 1997;349:1252.
27. Boudreaux JP, Hayes DH, Mizrahi S, Hussey J, Regenstein F, Balart L. Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minocycline hepatotoxicity. Transplant Proc 1993;25:1873.
28. Dussopt C, Mornex JF, Cordier FJ, Brune J. Poumon éosinophile aigu après prise de minocycline. Rev Mal Respir 1994;11:67-70.
29. Dykhuisen RS, Legge JS. Minocycline induced pulmonary eosinophilia. Respir Med 1995;89:61-2.
30. Elkayam O, Yaron M, Caspi D. Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA. Ann Rheum Dis 1996;55:769-71.
31. Golstein PE, Deviere J, Cremer M. Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol 1997;92: 143-6.
32. Gordon PM, White MI, Herriot R, Martin JC, Reid DM. Minocycline-associated lupus erythematosus. Br J Dermatol 1995;132:120-1.
33. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996;312:169-72.
34. Kaufmann D, Pichler W, Beer JH. Severe episode of high fever with rash, lymphadenopathy, neutropenia, and eosinophilia after minocycline therapy for acne. Arch Intern Med 1994;154:1983-4.
35. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 1996;132:934-9.
36. McNeil M, Haase DA, Tremaine R, Marrie TJ. Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatis: a severe adverse reaction to minocycline. J Am Acad Dermatol 1997;36:347-50.
37. Malcolm A, Heap TR, Eckstein RP, Lunzer MR. Minocycline-induced liver injury. Am J Gastroenterology 1996;91:1641-3.
38. Masson C, Chevallier A, Pascaretti C, Legrand E, Bregeon C, Audran M. Minocycline related lupus. J Rheumatol 1996;23:2160-1.
39. Lienart F, Morissens M, Jacobs P, Ducobu J. Doxycycline and hepatotoxicity. Acta Clin Belg 1992;74:205-8.
40. Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, Das K. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993;119:576-83.
41. Hunt CM, Washington K. Tetracycline induced bile duct paucity and prolonged cholestatis. Gastroenterology 1994;107:1844-7.
42. Björnsson E, Lindberg J, Olsson R. Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol 1997;32:390-5.
43. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997;133:1224-30.
44. Eady EA, Cove JH, Holland KT, Cunliffe WJ. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989;121:51-7.
45. Eady EA, Jones CE, Tipper JL, Cove JH, Cunliffe WJ, Layton AM. Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage. BMJ 1993;306:555-6.
46. Drake LA, et al. Guidelines of care for acne vulgaris. J Am Acad Dermatol 1990;22:676-80.
47. Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid. J Am Acad Dermatol 1980;3:602-11.
48. Kauffman RE, Banner W, Berlin C, Gorman RL, Lambert GH, Wilson G. American Academy of Pediatrics Committee on Drugs: Retinoid therapy for severe dermatological disorders. Pediatrics 1992;90:119-20.
49. Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 1992;27:52-7.
50. Peck GL, Olsen TG, Butkus D, Pandya M, Arnaud-Battandier J, Gross EG, Windhorst DB, Cheripko J, Nutley NJ. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982;6:735-45.
51. Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, Comite H, Exner JH. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984;10:490-6.
52. Cunliffe WJ, Layton AM. Oral isotretinoin: patient selection and management. J Dermatol Treat 1993;4:510-5.
53. Cunliffe WJ, Norris JFB. Isotretinoin an explanation for long-term benefit. Dermatologica 1987;175:133-7.
54. Jones DH, King K, Miller AJ, Cunliffe WJ. A dose-response study of 13-cis-retinoic acid in acne vulgaris. Br J Dermatol 1983;108:333-43.
55. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris; 10 years later: a safe and successful treatment. Br J Dermatol 1993;129:292-6.
56. Goulden V, Layton AM, Cunliffe WJ. Long-term safety of isotretinoin as a treatment for acne vulgaris. Br J Dermatol 1994;131:360-3.
57. White GM. Recurrence rates after the first course of isotretinoin. Arch Dermatol 1998;134:376-8.
58. Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993;186:123-8.
59. Harms M. Isotretinoin: 10 years on. Dermatology 1993;186:81-2.
60. Lehucher Ceyrac, Chapsoux C, Sulimovic L, Morel P, Lefrancq. Aggravation de l'acné sous isotrétinoïne. 6 cas, facteurs prédictifs. Ann Dermatol Venereol 1998;125:496-9.
61. Braun JJ, Franciosi RA, Mastri AR, Drake RM, O'Neil BL Isotretinoïn dysmorphic syndrom. Lancet 1984;1:506-7.
62. Lammer EJ, Chen DJ, Richard MH, Hoar RM, Agnish ND, Benke PJJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW, Lott IT, Richard JM, Sun SC. Retinoïc acid embryopathy. N Engl J Med 1985;313:837-41.
63. Rosa FW. Teratogenicity of isotretinoin. Lancet 1983;2:513.
64. Stern RS. Sounding board. When a uniquely effective drug is teratogenic. The case of isotretinoin. N Engl J Med 1989;320:1007-9.
65. Autret E, Radal M, Jonville-Bera AP, Goehrs JM. Isotrétinoïne (Roaccutane) chez la femme en âge de procréer: insuffisance de suivi des recommandations de prescription. Ann Dermatol Venereol 1997;124:518-22.
66. Bershad. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985;313:981-5.
67. Willoughby JS, Rosenthal D. Monitoring isotretinoin therapy in acne: rational use of laboratory tests. J Cut Med Surg 1997;2:72-7.
68. Erkkola R, Hiroven E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandogenic symptoms. Acta Obstet Gynecol Scand 1990;69:61-5.
69. Fugere P, Percival-Smith KL, Lussier-Cacan S, Davignon J, Farquhar D. Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose-response study of the estrogen component. Contraception 1990;42:225-34.
70. Dreno B, Amblard P, Agache P, Sirot S, Litoux P. Low doses of zinc gluconate for inflammatory acne. Acta Dermatol Venereol (Stockh) 1989; 69:541-3.
71. Karvonen SL. Acne fulminans: report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol 1993;28:572-9.
72. Karvonen SL, Vaalasti A, Kantiainen H, Reunala T. Systemic corticosteroid and isotretinoin treatment in cystic acne. Acta Dermatol Venereol (Stockh) 1993;73:452-5.
73. Rosenberg EW, Kirk BS. Acne diet reconsidered Arch Dermatol 1981;117:193-5.
74. Mensier A, Lopes P. Contraception: méthode, efficacité, choix, contre-indications, surveillance, risque. Rev Prat 1996;46:119-28.